Juno Therapeutics Inc (JUNO) was Downgraded by JP Morgan to ” Neutral” while Lowering the Price Target of the company shares to $ 39 from a previous price target of $63 . Earlier the firm had a rating of “Overweight ” on the company shares. JP Morgan advised their investors in a research report released on Jul 8, 2016.
Many Wall Street Analysts have commented on Juno Therapeutics Inc. Shares were Reiterated by FBR Capital on Jul 8, 2016 to “Outperform” and Lowered the Price Target to $ 61 from a previous price target of $73 .Raymond James Initiated Juno Therapeutics Inc on Jun 2, 2016 to “Outperform”, Price Target of the shares are set at $52.Company shares were Reiterated by Maxim Group on Apr 11, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $78 .
On the company’s financial health, Juno Therapeutics Inc reported $-0.78 EPS for the quarter, missing the analyst consensus estimate by $ -0.26 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $-0.52. The company had revenue of $9.80 million for the quarter, compared to analysts expectations of $3.15 million. During the same quarter in the previous year, the company posted $-0.30 EPS.
Juno Therapeutics Inc closed down -1.1 points or -2.70% at $39.59 with 7,01,074 shares getting traded on Tuesday. Post opening the session at $40.27, the shares hit an intraday low of $38.76 and an intraday high of $40.65 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at $40.71 per share price. According to the SEC, on Jun 21, 2016, Hyam Levitsky (EVP, Research & CSO) sold 12,418 shares at $42.98 per share price. On Jun 13, 2016, Steve Harr (CFO & Head, Corp. Development) sold 30,000 shares at $43.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.